Revista de otorrinolaringología y cirugía de cabeza y cuello
versión On-line ISSN 0718-4816
CARDEMIL, Felipe y DELANO, Paul H. Merlin and new treatments for vestibular schwannomas in patients with Neurofibromatosis type 2. Rev. Otorrinolaringol. Cir. Cabeza Cuello [online]. 2012, vol.72, n.2, pp. 195-202. ISSN 0718-4816. http://dx.doi.org/10.4067/S0718-48162012000200015.
Vestibular schwannomas are benign tumors that may occur bilaterally in the context of neurofibromatosis type 2 (NF2). A mutation in the NF2 gene coding for merlin protein has been identified in those cases associated with NF2. Merlin is a cytoplasmic protein localized in actin rich cell protrusions, and near contact sites between cells and extracellular matrix. The evidence suggests that merlin plays a role as tumor suppressor protein, regulating the activation cascade of different types of receptors for cell growth factors. Thus, merlin deficiency causes a pattern of increased cell proliferation, cytoskeletal alterations, decreased apoptosis and increased cell adhesion to the extracellular matrix. Several clinical therapies have been developed for NF2 patients including monoclonal antibodies and inhibitors directed against different molecules involved in cell signaling cascades modulated by merlin. In this article we review and discuss cellular mechanisms dependent of merlin and some clinical and experimental studies that have been studied in patients with NF2.
Palabras llave : bevacizumab; Merlin; Neurofibromatosis type 2; Vestibular Schwannoma; monoclonal antibodies; Bevacizumab.